RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Enemem, In Wednesday's press release they said RD-1 results would be in 'several weeeks' -

>>> A second respiratory depression study has been performed by a group in Frankfurt, Germany. This study uses a single dose of 1500mg of CX717 and focuses on both the respiratory depression and the analgesic effects associated with alfentanil. The analysis of the data has been initiated and related results should be reported within a few weeks. Studies of CX717 in animal models by Dr. John Greer at the University of Alberta have shown that the AMPAKINE drugs do not interfere with the analgesic effects of opiates. <<<